Top

Inflammation Research

Published in:

Open Access 28-09-2023 | Polymyalgia Arteritica | Review

Advances of autoimmune rheumatic diseases related to malignant tumors

Authors: Miaomiao Zhao, Liangyu Mi, Yuli Ji, Xiaoyao He, Yanan Gao, Yuting Hu, Ke Xu

Published in: Inflammation Research | Issue 10-11/2023

Abstract

Background

Malignant neoplasms are a well-recognized global public health concern, with significant impacts on human health and quality of life. The interplay between tumors and autoimmune rheumatic diseases is complex, and the resulting tumor-associated rheumatic diseases represent a rare and intricate group of conditions that occur in the context of malignant tumors. In addition, various rheumatic diseases can arise as a consequence of oncology treatment. These diseases present with intricate clinical manifestations and pathological features, often rendering them challenging to diagnose and impacting patients' quality of life. Despite this, they have yet to be fully recognized.

Methods

This article presents a literature review of published original articles and review articles concerning paraneoplastic rheumatic syndromes and rheumatic diseases associated with cancer treatment. We conducted a comprehensive literature search in PubMed, Web of Science and Google Scholar databases, excluding duplicated and irrelevant studies. In cases of duplicated research, we selected articles with higher impact factors for the review.

Results

This review focuses on the clinical features, diagnosis, and treatment of paraneoplastic rheumatic diseases, as well as the pathogenesis of these diseases. Additionally, we summarize the autoimmune rheumatic diseases associated with cancer treatment. Ultimately, the goal of this review is to enhance recognition and improve the management of autoimmune rheumatic diseases related to tumors.

András C, Csiki Z, Ponyi A, Illés A, Dankó K. Paraneoplastic rheumatic syndromes. Rheumatol Int. 2006;26:376–82. https://doi.org/10.1007/s00296-005-0005-3.CrossRefPubMed

Roberts J, Ennis D, Hudson M, Ye C, Saltman A, Himmel M, Rottapel R, Pope J, Hoa S, Tisseverasinghe A, Fifi-Mah A, Maltez N, Jamal S. Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort. Autoimmun Rev. 2020;19:102595. https://doi.org/10.1016/j.autrev.2020.102595.CrossRefPubMed

Xie W, Huang H, Xiao S, Fan Y, Deng X, Zhang Z. Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: a meta-analysis of observational studies. Autoimmun Rev. 2020;19: 102687. https://doi.org/10.1016/j.autrev.2020.102687.CrossRefPubMed

Eisenlohr LC, Rothstein JL. Oncogenic inflammation and autoimmune disease. Autoimmun Rev. 2006;6:107–14. https://doi.org/10.1016/j.autrev.2006.04.002.CrossRefPubMed

Bosman A, Palermo A, Vanderhulst J, De Beur SMJ, Fukumoto S, Minisola S, Xia W, Body J-J, Zillikens MC. Tumor-induced osteomalacia: a systematic clinical review of 895 cases. Calcif Tissue Int. 2022. https://doi.org/10.1007/s00223-022-01005-8.CrossRefPubMedPubMedCentral

Hidaka N, Koga M, Kimura S, Hoshino Y, Kato H, Kinoshita Y, Makita N, Nangaku M, Horiguchi K, Furukawa Y, Ohnaka K, Inagaki K, Nakagawa A, Suzuki A, Takeuchi Y, Fukumoto S, Nakatani F, Ito N. Clinical challenges in diagnosis, tumor localization and treatment of tumor-induced osteomalacia: outcome of a retrospective surveillance. J Bone Miner Res. 2022;37:1479–88. https://doi.org/10.1002/jbmr.4620.CrossRefPubMed

Azar L, Khasnis A. Paraneoplastic rheumatologic syndromes. Curr Opin Rheumatol. 2013;25:44–9. https://doi.org/10.1097/BOR.0b013e328359e780.CrossRefPubMed

Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA. 2001;98:6500–5.CrossRefPubMedPubMedCentral

Nakanishi R, Shimizu M, Mori M, Akiyama H, Okudaira S, Otsuki B, Hashimoto M, Higuchi K, Hosokawa M, Tsuboyama T, Nakamura T. Secreted frizzled-related protein 4 is a negative regulator of peak BMD in SAMP6 mice. J Bone Miner Res. 2006;21:1713–21. https://doi.org/10.1359/jbmr.060719.CrossRefPubMed

10.

Berndt TJ, Schiavi S, Kumar R. “Phosphatonins” and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol. 2005;289:F1170-1182. https://doi.org/10.1152/ajprenal.00072.2005.CrossRefPubMed

11.

Kani KK, Porrino JA, Mulligan ME, Chew FS. Paraneoplastic musculoskeletal disorders: review and update for radiologists. Skeletal Radiol. 2022. https://doi.org/10.1007/s00256-022-04074-w.CrossRefPubMed

12.

Pfinsgraff J, Buckingham RB, Killian PJ, Keister SR, Brereton WF, Weinblatt ME, George DL, Arnett FC. Palmar fasciitis and arthritis with malignant neoplasms: a paraneoplastic syndrome. Semin Arthritis Rheum. 1986;16:118–25. https://doi.org/10.1016/0049-0172(86)90045-4.CrossRefPubMed

13.

Manger B, Schett G. Palmar fasciitis and polyarthritis syndrome-systematic literature review of 100 cases. Semin Arthritis Rheum. 2014;44:105–11. https://doi.org/10.1016/j.semarthrit.2014.03.005.CrossRefPubMed

14.

Nadal R, McMahan ZH, Antonarakis ES. Paraneoplastic palmar fasciitis and polyarthritis syndrome in a patient with advanced prostate cancer. Clin Genitourin Cancer. 2013;11:e15-23. https://doi.org/10.1016/j.clgc.2013.05.008.CrossRefPubMedPubMedCentral

15.

Qureshi AA, Saavedra A. Palmar fasciitis and polyarthritis syndrome in patients with ovarian cancer-a case report and review of the literature. Hand (N Y). 2011;6:220–3. https://doi.org/10.1007/s11552-010-9310-8.CrossRefPubMed

16.

Okumura H, Ishino H, Yokoi D, Matsumura M. Palmar fasciitis and polyarthritis syndrome associated with lung adenocarcinoma. Intern Med. 2022;61:2221–5. https://doi.org/10.2169/internalmedicine.8619-21.CrossRefPubMed

17.

van Marcke C, Seront E, Docquier C, Filleul B. Palmar fasciitis and polyarthritis, a rare paraneoplastic syndrome related to ovarian cancer. Clin Exp Dermatol. 2017;42:328–30. https://doi.org/10.1111/ced.13071.CrossRefPubMed

18.

Celen H, Neerinckx B. Palmar fasciitis and polyarthritis: an uncommon but remarkable paraneoplastic syndrome. Clin Rheumatol. 2021;40:2507–8. https://doi.org/10.1007/s10067-020-05552-z.CrossRefPubMed

19.

Yogarajah M, Soh J, Lord B, Goddard N, Stratton R. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101:473–5. https://doi.org/10.1258/jrsm.2008.080060.CrossRefPubMedPubMedCentral

20.

Martínez-Lavín M. Hypertrophic osteoarthropathy. Best Pract Res Clin Rheumatol. 2020;34: 101507. https://doi.org/10.1016/j.berh.2020.101507.CrossRefPubMed

21.

Uppal S, Diggle CP, Carr IM, Fishwick CWG, Ahmed M, Ibrahim GH, Helliwell PS, Latos-Bieleńska A, Phillips SEV, Markham AF, Bennett CP, Bonthron DT. Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet. 2008;40:789–93. https://doi.org/10.1038/ng.153.CrossRefPubMed

22.

Zhang Z, Xia W, He J, Zhang Z, Ke Y, Yue H, Wang C, Zhang H, Gu J, Hu W, Fu W, Hu Y, Li M, Liu Y. Exome sequencing identifies SLCO2A1 mutations as a cause of primary hypertrophic osteoarthropathy. Am J Hum Genet. 2012;90:125–32. https://doi.org/10.1016/j.ajhg.2011.11.019.CrossRefPubMedPubMedCentral

23.

Dong Z, Xia J, Wan X. A rare helicobacter pylori infection-negative early gastric cancer in a young man with primary hypertrophic osteoarthropathy. Endoscopy. 2022;54:E612–4. https://doi.org/10.1055/a-1722-2336.CrossRefPubMed

24.

Dong J, Bian D, Feng Q. Gastrointestinal multiple adenomas in primary hypertrophic osteoarthropathy. Mayo Clin Proc. 2022;97:941–2. https://doi.org/10.1016/j.mayocp.2022.02.030.CrossRefPubMed

25.

Yap FY, Skalski MR, Patel DB, Schein AJ, White EA, Tomasian A, Masih S, Matcuk GR. Hypertrophic osteoarthropathy: clinical and imaging features. Radiographics. 2017;37:157–95. https://doi.org/10.1148/rg.2017160052.CrossRefPubMed

26.

Vandemergel X, Blocklet D, Decaux G. Periostitis and hypertrophic osteoarthropathy: etiologies and bone scan patterns in 115 cases. Eur J Intern Med. 2004;15:375–80. https://doi.org/10.1016/j.ejim.2004.04.017.CrossRefPubMed

27.

Dickinson CJ, Martin JF. Megakaryocytes and platelet clumps as the cause of finger clubbing. Lancet. 1987;2:1434–5. https://doi.org/10.1016/s0140-6736(87)91132-9.CrossRefPubMed

28.

Strunz P-P, Schmalzing M. Paraneoplastic syndromes in rheumatology. Z Rheumatol. 2023. https://doi.org/10.1007/s00393-022-01314-1.CrossRefPubMed

29.

Karmacharya P, Donato AA, Aryal MR, Ghimire S, Pathak R, Shah K, Shrestha P, Poudel D, Wasser T, Subedi A, Giri S, Jalota L, Olivé A. RS3PE revisited: a systematic review and meta-analysis of 331 cases. Clin Exp Rheumatol. 2016;34:404–15.PubMed

30.

Chou E, Suzuma I, Way KJ, Opland D, Clermont AC, Naruse K, Suzuma K, Bowling NL, Vlahos CJ, Aiello LP, King GL. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic states: a possible explanation for impaired collateral formation in cardiac tissue. Circulation. 2002;105:373–9. https://doi.org/10.1161/hc0302.102143.CrossRefPubMed

31.

Olivé A, del Blanco J, Pons M, Vaquero M, Tena X. The clinical spectrum of remitting seronegative symmetrical synovitis with pitting edema. The Catalán Group for the Study of RS3PE. J Rheumatol. 1997;24:333–6.PubMed

32.

Zupancic M, Annamalai A, Brenneman J, Ranatunga S. Migratory polyarthritis as a paraneoplastic syndrome. J Gen Intern Med. 2008;23:2136–9. https://doi.org/10.1007/s11606-008-0794-7.CrossRefPubMedPubMedCentral

33.

Lee SJ, Yeo SG, Kim HK, Park DC. Paraneoplastic arthritis mimicking rheumatoid arthritis in cervical cancer. Eur J Gynaecol Oncol. 2014;35:728–30.PubMed

34.

Kisacik B, Onat AM, Kasifoglu T, Pehlivan Y, Pamuk ON, Dalkilic E, Donmez S, Bilge SY, Yilmaz S, Erdem H, Mercan R, Ozturk MA, Bes C, Soy M, Erten S, Cobankara V, Senel S, Oner FA, Direskeneli H, Yilmaz S, Yazici A, Emmungil H, Aksu K, Kul S, Cetin GY, Sayarlioglu M. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17:640–5. https://doi.org/10.1111/1756-185X.12277.CrossRefPubMed

35.

Schultz H, Krenn V, Tony HP. Oligoarthritis mediated by tumor-specific T lymphocytes in renal-cell carcinoma. N Engl J Med. 1999;341:290–1. https://doi.org/10.1056/NEJM199907223410415.CrossRefPubMed

36.

Brentville VA, Metheringham RL, Gunn B, Symonds P, Daniels I, Gijon M, Cook K, Xue W, Durrant LG. Citrullinated vimentin presented on MHC-II in tumor cells is a target for CD4+ T-Cell-mediated antitumor immunity. Cancer Res. 2016;76:548–60. https://doi.org/10.1158/0008-5472.CAN-15-1085.CrossRefPubMed

37.

Morel J, Deschamps V, Toussirot E, Pertuiset E, Sordet C, Kieffer P, Berthelot JM, Champagne H, Mariette X, Combe B. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244–7. https://doi.org/10.1136/ard.2007.070086.CrossRefPubMed

38.

Yamashita H, Ueda Y, Ozaki T, Tsuchiya H, Takahashi Y, Kaneko H, Kano T, Mimori A. Characteristics of 10 patients with paraneoplastic rheumatologic musculoskeletal manifestations. Mod Rheumatol. 2014;24:492–8. https://doi.org/10.3109/14397595.2013.843762.CrossRefPubMed

39.

Kang EH, Lee SJ, Ascherman DP, Lee YJ, Lee EY, Lee EB, Song YW. Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis. Rheumatology (Oxf). 2016;55:1631–41. https://doi.org/10.1093/rheumatology/kew215.CrossRef

40.

Tiniakou E, Mammen AL. Idiopathic inflammatory myopathies and malignancy: a comprehensive review. Clin Rev Allergy Immunol. 2017;52:20–33. https://doi.org/10.1007/s12016-015-8511-x.CrossRefPubMed

41.

Yang Z, Lin F, Qin B, Liang Y, Zhong R. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol. 2015;42:282–91. https://doi.org/10.3899/jrheum.140566.CrossRefPubMed

42.

Moghadam-Kia S, Oddis CV, Ascherman DP, Aggarwal R. Risk factors and cancer screening in myositis. Rheum Dis Clin North Am. 2020;46:565–76. https://doi.org/10.1016/j.rdc.2020.05.006.CrossRefPubMed

43.

Qiang JK, Kim WB, Baibergenova A, Alhusayen R. Risk of malignancy in dermatomyositis and polymyositis. J Cutan Med Surg. 2017;21:131–6. https://doi.org/10.1177/1203475416665601.CrossRefPubMed

44.

Airio A, Pukkala E, Isomäki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol. 1995;22:1300–3.PubMed

45.

András C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P, Dankó K. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35:438–44.PubMed

46.

Chinoy H, Fertig N, Oddis CV, Ollier WER, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis. 2007;66:1345–9. https://doi.org/10.1136/ard.2006.068502.CrossRefPubMedPubMedCentral

47.

Trallero-Araguás E, Rodrigo-Pendás JÁ, Selva-O’Callaghan A, Martínez-Gómez X, Bosch X, Labrador-Horrillo M, Grau-Junyent JM, Vilardell-Tarrés M. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64:523–32. https://doi.org/10.1002/art.33379.CrossRefPubMed

48.

Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, Corse A, Rosen A. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med. 2005. https://doi.org/10.1084/jem.20041367.CrossRefPubMedPubMedCentral

49.

Fujikawa K, Kawakami A, Kaji K, Fujimoto M, Kawashiri S, Iwamoto N, Aramaki T, Ichinose K, Tamai M, Kamachi M, Nakamura H, Ida H, Origuchi T, Ishimoto H, Mukae H, Kuwana M, Kohno S, Takehara K, Sato S, Eguchi K. Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol. 2009;38:263–7. https://doi.org/10.1080/03009740802687455.CrossRefPubMed

50.

Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, Rosen A, Casciola-Rosen L. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum. 2013;65:2954–62. https://doi.org/10.1002/art.38093.CrossRefPubMedPubMedCentral

51.

Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K, Matsushita T, Orito H, Hamaguchi Y, Yanaba K, Itoh M, Asano Y, Seishima M, Ogawa F, Sato S, Takehara K. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxf). 2007;46:25–8. https://doi.org/10.1093/rheumatology/kel161.CrossRef

52.

Andrieux G, Fattet L, Le Borgne M, Rimokh R, Théret N. Dynamic regulation of Tgf-B signaling by Tif1γ: a computational approach. PLoS ONE. 2012;7: e33761. https://doi.org/10.1371/journal.pone.0033761.CrossRefPubMedPubMedCentral

53.

Wang L, Yang H, Lei Z, Zhao J, Chen Y, Chen P, Li C, Zeng Y, Liu Z, Liu X, Zhang H-T. Repression of TIF1γ by SOX2 promotes TGF-β-induced epithelial–mesenchymal transition in non-small-cell lung cancer. Oncogene. 2016;35:867–77. https://doi.org/10.1038/onc.2015.141.CrossRefPubMed

54.

Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, Inokoshi Y, Kawai K, Kanekura T, Habuchi M, Igarashi A, Sogame R, Hashimoto T, Koga T, Nishino A, Ishiguro N, Sugimoto N, Aoki R, Ando N, Abe T, Kanda T, Kuwana M, Takehara K, Fujimoto M. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;71:710–3. https://doi.org/10.1136/annrheumdis-2011-200697.CrossRefPubMed

55.

Betrains A, Rosseels W, Van Mieghem E, Vanderschueren S, Nijs J. Clinical characteristics, treatment, and outcome of pancreatitis, panniculitis, and polyarthritis syndrome: a case-based review. Clin Rheumatol. 2021;40:1625–33. https://doi.org/10.1007/s10067-020-05333-8.CrossRefPubMed

56.

Yasuda MR, Roller LA, Fagenholz PJ, Hoang MP. Case 33–2020: a 55-year-old man with abdominal pain, joint swelling, and skin lesions. N Engl J Med. 2020;383:1664–71. https://doi.org/10.1056/NEJMcpc1916257.CrossRefPubMed

57.

Narváez J, Bianchi MM, Santo P, de la Fuente D, Ríos-Rodriguez V, Bolao F, Narváez JA, Nolla JM. Pancreatitis, panniculitis, and polyarthritis. Semin Arthritis Rheum. 2010;39:417–23. https://doi.org/10.1016/j.semarthrit.2008.10.001.CrossRefPubMed

58.

Tupalli A, Angamuthu M, Prashanth A, Singh R, Kumar R. Intraosseous medullary fat necrosis on 99mTc-MDP bone scan of patient with acute pancreatitis. Clin Nucl Med. 2020;45:e294–5. https://doi.org/10.1097/RLU.0000000000003022.CrossRefPubMed

59.

Kang DJ, Lee SJ, Choo HJ, Her M, Yoon HK. Pancreatitis, panniculitis, and polyarthritis (PPP) syndrome: MRI features of intraosseous fat necrosis involving the feet and knees. Skeletal Radiol. 2017;46:279–85. https://doi.org/10.1007/s00256-016-2549-6.CrossRefPubMed

60.

Parperis K, Constantinidou A, Panos G. Paraneoplastic arthritides: insights to pathogenesis, diagnostic approach, and treatment. J Clin Rheumatol. 2021;27:e505–9. https://doi.org/10.1097/RHU.0000000000001202.CrossRefPubMed

61.

Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA. 2016;315:2442–58. https://doi.org/10.1001/jama.2016.5444.CrossRefPubMed

62.

Raheel S, Shbeeb I, Crowson CS, Matteson EL. Epidemiology of polymyalgia rheumatica 2000–2014 and examination of incidence and survival trends over 45 years: a population-based study. Arthritis Care Res (Hoboken). 2017;69:1282–5. https://doi.org/10.1002/acr.23132.CrossRefPubMed

63.

Matteson EL, Dejaco C. Polymyalgia rheumatica. Ann Intern Med. 2017;166:ITC65–80. https://doi.org/10.7326/AITC201705020.CrossRefPubMed

64.

van der Geest KSM, Abdulahad WH, Rutgers A, Horst G, Bijzet J, Arends S, Roffel MP, Boots AMH, Brouwer E. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. Rheumatology (Oxf). 2015;54:1397–402. https://doi.org/10.1093/rheumatology/keu526.CrossRef

65.

Yuge S, Nakatani K, Yoshino K, Koyama T. Diagnosing polymyalgia rheumatica on 18F-FDG PET/CT: typical uptake patterns. Ann Nucl Med. 2018;32:573–7. https://doi.org/10.1007/s12149-018-1269-5.CrossRefPubMed

66.

Espinosa G, Font J, Muñoz-Rodríguez FJ, Cervera R, Ingelmo M. Myelodysplastic and myeloproliferative syndromes associated with giant cell arteritis and polymyalgia rheumatica: a coincidental coexistence or a causal relationship? Clin Rheumatol. 2002;21:309–13. https://doi.org/10.1007/s100670200081.CrossRefPubMed

67.

Naschitz JE. Rheumatic syndromes: clues to occult neoplasia. Curr Opin Rheumatol. 2001;13:62–6. https://doi.org/10.1097/00002281-200101000-00010.CrossRefPubMed

68.

Manger B, Schett G. Rheumatic paraneoplastic syndromes—a clinical link between malignancy and autoimmunity. Clin Immunol. 2018;186:67–70. https://doi.org/10.1016/j.clim.2017.07.021.CrossRefPubMed

69.

Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37:593–606. https://doi.org/10.1016/j.rdc.2011.09.002.CrossRefPubMed

70.

Loricera J, Calvo-Río V, Ortiz-Sanjuán F, González-López MA, Fernández-Llaca H, Rueda-Gotor J, Gonzalez-Vela MC, Alvarez L, Mata C, González-Lamuño D, Martínez-Taboada VM, González-Gay MA, Blanco R. The spectrum of paraneoplastic cutaneous vasculitis in a defined population: incidence and clinical features. Medicine (Baltimore). 2013;92:331–43. https://doi.org/10.1097/MD.0000000000000009.CrossRefPubMed

71.

Solans-Laqué R, Bosch-Gil JA, Pérez-Bocanegra C, Selva-O’Callaghan A, Simeón-Aznar CP, Vilardell-Tarres M. Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases. J Rheumatol. 2008;35:294–304.PubMed

72.

Szekanecz Z, Szekanecz E, Bakó G, Shoenfeld Y. Malignancies in autoimmune rheumatic diseases—a mini-review. Gerontology. 2011;57:3–10. https://doi.org/10.1159/000314634.CrossRefPubMed

73.

Hynne H, Aqrawi LA, Jensen JL, Thiede B, Palm Ø, Amdal CD, Westgaard KL, Herlofson BB, Utheim TP, Galtung HK. Proteomic profiling of saliva and tears in radiated head and neck cancer patients as compared to primary Sjögren’s syndrome patients. Int J Mol Sci. 2022;23:3714. https://doi.org/10.3390/ijms23073714.CrossRefPubMedPubMedCentral

74.

Davis DA, Cohen PR, McNeese MD, Duvic M. Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: radiation port scleroderma. J Am Acad Dermatol. 1996;35:923–7. https://doi.org/10.1016/s0190-9622(96)90116-4.CrossRefPubMed

75.

Smith KJ, Yeager J, Skelton HG. Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: radiation port scleroderma. J Am Acad Dermatol. 1997;37:806–8. https://doi.org/10.1016/s0190-9622(97)70130-0.CrossRefPubMed

76.

Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117:557–67. https://doi.org/10.1172/JCI31139.CrossRefPubMedPubMedCentral

77.

Shah DJ, Hirpara R, Poelman CL, Woods A, Hummers LK, Wigley FM, Wright JL, Parekh A, Steen VD, Domsic RT, Shah AA. Impact of radiation therapy on scleroderma and cancer outcomes in scleroderma patients with breast cancer. Arthritis Care Res (Hoboken). 2018;70:1517–24. https://doi.org/10.1002/acr.23505.CrossRefPubMed

78.

Clowse MEB, Wigley FM. Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis. J Rheumatol. 2003;30:1341–3.PubMed

79.

Yamada Y, Suzuki K, Nobata H, Kawai H, Wakamatsu R, Miura N, Banno S, Imai H. Gemcitabine-induced hemolytic uremic syndrome mimicking scleroderma renal crisis presenting with Raynaud’s phenomenon, positive antinuclear antibodies and hypertensive emergency. Intern Med. 2014;53:445–8. https://doi.org/10.2169/internalmedicine.53.1160.CrossRefPubMed

80.

Inaoki M, Kawabata C, Nishijima C, Yoshio N, Kita T. Case of bleomycin-induced scleroderma. J Dermatol. 2012;39:482–4. https://doi.org/10.1111/j.1346-8138.2011.01301.x.CrossRefPubMed

81.

Park G-T, Yoon J-W, Yoo S-B, Song Y-C, Song P, Kim H-K, Han J, Bae S-J, Ha K-T, Mishchenko NP, Fedoreyev SA, Stonik VA, Kim M-B, Kim J-H. Echinochrome a treatment alleviates fibrosis and inflammation in bleomycin-induced scleroderma. Mar Drugs. 2021;19:237. https://doi.org/10.3390/md19050237.CrossRefPubMedPubMedCentral

82.

Hamaguchi Y. Drug-induced scleroderma-like lesion. Allergol Int. 2022;71:163–8. https://doi.org/10.1016/j.alit.2021.08.005.CrossRefPubMed

83.

Okada K, Endo Y, Miyachi Y, Koike Y, Kuwatsuka Y, Utani A. Glycosaminoglycan and versican deposits in taxane-induced sclerosis. Br J Dermatol. 2015;173:1054–8. https://doi.org/10.1111/bjd.13899.CrossRefPubMed

84.

Werquin S, Kacet S, Caron J, Lacroix D, Libersa C, Coget JM, Lekieffre J. Raynaud's phenomenon and finger necrosis after treatment of ovarian seminoma with bleomycin, vinblastine and 5-fluorouracil. In Annales de Cardiologie et D’angeiologie 1987;36(8):409-412.

85.

Mohokum M, Hartmann P, Schlattmann P. The association of Raynaud's syndrome with cisplatin-based chemotherapy—A meta-analysis. Eur Inter Med. 2012;23(7):594–8. https://doi.org/10.1016/j.ejim.2012.03.016.CrossRef

86.

Lintermans A, Van Asten K, Jongen L, Van Brussel T, Laenen A, Verhaeghe J, Vanderschueren D, Lambrechts D, Neven P. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients. Eur J Cancer. 2016;56:31–6. https://doi.org/10.1016/j.ejca.2015.12.013.CrossRefPubMed

87.

Hertz DL, Smith KL, Zong Y, Gersch CL, Pesch AM, Lehman J, Blackford AL, Henry NL, Kidwell KM, Rae JM, Stearns V. Further evidence that OPG rs2073618 is associated with increased risk of musculoskeletal symptoms in patients receiving aromatase inhibitors for early breast cancer. Front Genet. 2021;12: 662734. https://doi.org/10.3389/fgene.2021.662734.CrossRefPubMedPubMedCentral

88.

Wagstaff AJ, Ibbotson T, Goa KL. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs. 2003;63:217–36. https://doi.org/10.2165/00003495-200363020-00009.CrossRefPubMed

89.

Gadisa DA, Assefa M, Wang SH, Yimer G. Toxicity profile of Doxorubicin-Cyclophosphamide and Doxorubicin-Cyclophosphamide followed by Paclitaxel regimen and its associated factors among women with breast cancer in Ethiopia: A prospective cohort study. J Oncol Pharm Pract. 2020;26(8):1912-20. https://doi.org/10.1177/1078155220907658.CrossRefPubMed

90.

Chan BS, Dawson AH, Buckley NA. What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning?. Clin Toxicol 2017;55(2):88-96. https://doi.org/10.1080/15563650.2016.1271126.CrossRef

91.

Fenlon D, Addington-Hall JM, O’Callaghan AC, Clough J, Nicholls P, Simmonds P. A survey of joint and muscle aches, pain, and stiffness comparing women with and without breast cancer. J Pain Symptom Manage. 2013;46(4):523–35. https://doi.org/10.1016/j.jpainsymman.2012.10.282.CrossRefPubMed

92.

Cohen IS, Mosher MB, O’Keefe EJ, Klaus SN, De Conti RC. Cutaneous toxicity of bleomycin therapy. Arch Dermatol. 1973;107:553–5.CrossRefPubMed

93.

Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer. 2002;87:21–7. https://doi.org/10.1038/sj.bjc.6600347.CrossRefPubMedPubMedCentral

94.

Barnes TC, Spiller DG, Anderson ME, Edwards SW, Moots RJ. Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin 6 trans-signalling: a novel target for systemic sclerosis? Ann Rheum Dis. 2011;70:366–72. https://doi.org/10.1136/ard.2010.133587.CrossRefPubMed

95.

Liu M, Wang L, Bongartz T, Hawse JR, Markovic SN, Schaid DJ, Mushiroda T, Kubo M, Nakamura Y, Kamatani N, Goss PE, Ingle JN, Weinshilboum RM. Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. Breast Cancer Res. 2012;14:R41. https://doi.org/10.1186/bcr3137.CrossRefPubMedPubMedCentral

96.

Hertz DL, Douglas JA, Miller RM, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM. Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms. Support Care Cancer. 2022;30:8059–67. https://doi.org/10.1007/s00520-022-07243-8.CrossRefPubMedPubMedCentral

97.

D’Elia HF, Mattsson L-A, Ohlsson C, Nordborg E, Carlsten H. Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. Arthritis Res Ther. 2003;5:R202-209. https://doi.org/10.1186/ar761.CrossRefPubMedPubMedCentral

98.

Smith YR, Stohler CS, Nichols TE, Bueller JA, Koeppe RA, Zubieta J-K. Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. J Neurosci. 2006;26:5777–85. https://doi.org/10.1523/JNEUROSCI.5223-05.2006.CrossRefPubMedPubMedCentral

99.

Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–68. https://doi.org/10.1056/NEJMra1703481.CrossRefPubMed

100.

Tocut M, Brenner R, Zandman-Goddard G. Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 2018;17:610–6. https://doi.org/10.1016/j.autrev.2018.01.010.CrossRefPubMed

101.

Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19:254–67. https://doi.org/10.1038/s41571-022-00600-w.CrossRefPubMedPubMedCentral

102.

Zhang S, Zhou Z, Wang L, Li M, Zhang F, Zeng X. Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis. Ther Adv Chronic Dis. 2021. https://doi.org/10.1177/2040622320976996.CrossRefPubMedPubMedCentral

103.

Shen P, Deng X, Hu Z, Chen Z, Huang Y, Wang K, Qin K, Huang Y, Ba X, Yan J, Han L, Tu S. Rheumatic manifestations and diseases from immune checkpoint inhibitors in cancer immunotherapy. Front Med (Lausanne). 2021;8: 762247. https://doi.org/10.3389/fmed.2021.762247.CrossRefPubMed

104.

Verspohl SH, Holderried T, Behning C, Brossart P, Schäfer VS. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis. Ther Adv Musculoskelet Dis. 2021. https://doi.org/10.1177/1759720X211006963.CrossRefPubMedPubMedCentral

105.

Ghosh N, Tiongson MD, Stewart C, Chan KK, Jivanelli B, Cappelli L, Bass AR. Checkpoint inhibitor-associated arthritis: a systematic review of case reports and case series. J Clin Rheumatol Pract Rep Rheum Musculoskel Dis. 2021. https://doi.org/10.1097/RHU.0000000000001370.CrossRef

106.

Cappelli LC, Brahmer JR, Forde PM, Le DT, Lipson EJ, Naidoo J, Zheng L, Bingham CO, Shah AA. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum. 2018;48:553–7. https://doi.org/10.1016/j.semarthrit.2018.02.011.CrossRefPubMedPubMedCentral

107.

Belkhir R, Burel SL, Dunogeant L, Marabelle A, Hollebecque A, Besse B, Leary A, Voisin A-L, Pontoizeau C, Coutte L, Pertuiset E, Mouterde G, Fain O, Lambotte O, Mariette X. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017;76:1747–50. https://doi.org/10.1136/annrheumdis-2017-211216.CrossRefPubMed

108.

Leipe J, Christ LA, Arnoldi AP, Mille E, Berger F, Heppt M, Goldscheider I, Kauffmann-Guerrero D, Huber RM, Dechant C, Berking C, Schulze-Koops H, Skapenko A. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open. 2018;4: e000714. https://doi.org/10.1136/rmdopen-2018-000714.CrossRefPubMedPubMedCentral

109.

Gómez-Puerta JA, Lobo-Prat D, Perez-García C, Ponce A, Frade-Sosa B, Millán Arciniegas AM, Ojeda F, Ruiz-Esquide V, Corominas H. Clinical patterns and follow-up of inflammatory arthritis and other immune-related adverse events induced by checkpoint inhibitors. A multicenter study. Front Med (Lausanne). 2022;9(2022): 888377. https://doi.org/10.3389/fmed.2022.888377.CrossRefPubMedPubMedCentral

110.

Ibañez-Vega J, Vilchez C, Jimenez K, Guevara C, Burgos PI, Naves R. Cellular and molecular regulation of the programmed death-1/programmed death ligand system and its role in multiple sclerosis and other autoimmune diseases. J Autoimmun. 2021;123: 102702. https://doi.org/10.1016/j.jaut.2021.102702.CrossRefPubMed

111.

Raptopoulou AP, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I, Tzardi M, Klareskog L, Catrina AI, Sidiropoulos P, Boumpas DT. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum. 2010;62:1870–80. https://doi.org/10.1002/art.27500.CrossRefPubMed

112.

Reid P, Liew DF, Akruwala R, Bass AR, Chan KK. Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study. J Immunother Cancer. 2021;9: e003260. https://doi.org/10.1136/jitc-2021-003260.CrossRefPubMedPubMedCentral

113.

Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, Dousset L, Pham-Ledard A, Prey S, Beylot-Barry M, Daste A, Gross-Goupil M, Lallier J, Ravaud A, Forcade E, Bannwarth B, Truchetet M-E, Richez C, Mehsen N, Schaeverbeke T. FHU ACRONIM, Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018;77:393–8. https://doi.org/10.1136/annrheumdis-2017-212257.CrossRefPubMed

114.

Anquetil C, Salem J-E, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, Léonard-Louis S, Benveniste O, Moslehi JJ, Allenbach Y. Immune checkpoint inhibitor-associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution. Circulation. 2018;138:743–5. https://doi.org/10.1161/CIRCULATIONAHA.118.035898.CrossRefPubMed

115.

Shah M, Tayar JH, Abdel-Wahab N, Suarez-Almazor ME. Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Semin Arthritis Rheum. 2019;48:736–40. https://doi.org/10.1016/j.semarthrit.2018.05.006.CrossRefPubMed

116.

Seki M, Uruha A, Ohnuki Y, Kamada S, Noda T, Onda A, Ohira M, Isami A, Hiramatsu S, Hibino M, Nakane S, Noda S, Yutani S, Hanazono A, Yaguchi H, Takao M, Shiina T, Katsuno M, Nakahara J, Matsubara S, Nishino I, Suzuki S. Inflammatory myopathy associated with PD-1 inhibitors. J Autoimmun. 2019;100:105–13. https://doi.org/10.1016/j.jaut.2019.03.005.CrossRefPubMed

117.

Touat M, Maisonobe T, Knauss S, Salem OBH, Hervier B, Auré K, Szwebel T-A, Kramkimel N, Lethrosne C, Bruch J-F, Laly P, Cadranel J, Weiss N, Béhin A, Allenbach Y, Benveniste O, Lenglet T, Psimaras D, Stenzel W, Léonard-Louis S. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology. 2018;91:e985–94. https://doi.org/10.1212/WNL.0000000000006124.CrossRefPubMed

118.

Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA, Anders RA, Sosman JA, Moslehi JJ. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–55. https://doi.org/10.1056/NEJMoa1609214.CrossRefPubMedPubMedCentral

119.

Allenbach Y, Anquetil C, Manouchehri A, Benveniste O, Lambotte O, Lebrun-Vignes B, Spano J-P, Ederhy S, Klatzmann D, Rosenzwajg M, Fautrel B, Cadranel J, Johnson DB, Moslehi JJ, Salem J-E. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun Rev. 2020;19: 102586. https://doi.org/10.1016/j.autrev.2020.102586.CrossRefPubMed

120.

Warner BM, Baer AN, Lipson EJ, Allen C, Hinrichs C, Rajan A, Pelayo E, Beach M, Gulley JL, Madan RA, Feliciano J, Grisius M, Long L, Powers A, Kleiner DE, Cappelli L, Alevizos I. Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist. 2019;24:1259–69. https://doi.org/10.1634/theoncologist.2018-0823.CrossRefPubMedPubMedCentral

121.

Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol. 2018;37:2579–84. https://doi.org/10.1007/s10067-018-4177-0.CrossRefPubMed

122.

Chanson N, Ramos-Casals M, Pundole X, Suijkerbuijk K, José de Barros M, Silva E, Lidar M, Benesova K, Leipe J, Acar-Denizli N, Pradère P, Michot J-M, Voisin A-L, Suárez-Almazor ME, Radstake TRD, Trevisani VFM, Schulze-Koops H, Melin A, Robert C, Mariette X, Baughman RP, Lambotte O, ICIR, Coordination, Co-Convenors, Steering Committee, Research Fellows, Data Scientist. Immune checkpoint inhibitor-associated sarcoidosis: a usually benign disease that does not require immunotherapy discontinuation. Eur J Cancer. 2021;158:208–16. https://doi.org/10.1016/j.ejca.2021.05.041.CrossRefPubMed

123.

Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60. https://doi.org/10.1016/j.ctrv.2016.02.001.CrossRefPubMed

Title: Advances of autoimmune rheumatic diseases related to malignant tumors
Authors: Miaomiao Zhao
Liangyu Mi
Yuli Ji
Xiaoyao He
Yanan Gao
Yuting Hu
Ke Xu
Publication date: 28-09-2023
Publisher: Springer International Publishing
Keywords: Polymyalgia Arteritica
Polymyalgia Arteritica
Published in: Inflammation Research / Issue 10-11/2023
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-023-01780-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Please log in to get access to this content

Other articles of this Issue 10-11/2023

Ångstrom-scale silver particles ameliorate collagen-induced and K/BxN-transfer arthritis in mice via the suppression of inflammation and osteoclastogenesis

Fraxetin alleviates BLM-induced idiopathic pulmonary fibrosis by inhibiting NCOA4-mediated epithelial cell ferroptosis

Kinins: Locally formed peptides during inflammation with potential use in tissue regeneration

Targeting MyD88: Therapeutic mechanisms and potential applications of the specific inhibitor ST2825

A common variant close to the “tripwire” linker region of NLRP1 contributes to severe COVID-19

Recombinant human diamine oxidase prevents hemodynamic effects of continuous histamine infusion in guinea pigs

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage